Phase 2 N=55 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Phase 2 N=58 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
Phase 2 N=65 Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Ovarian Cancer
Primary: Objective Tumor Response — 12.5; 12.1 percentage of participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 3 N=107 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: 6 Month Progression-free Survival Rate (PFS) (Based on Combined Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 +/- Gynecologic Cancer Intergroup (GCIG)…
Phase 2 N=36 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
Phase 2 N=31 Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Adult Type Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma · Ovarian Sertoli-Leydig Cell Tumor
Primary: Probability of Complete Clinical Response — 3.2 Percentage of Participants
Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Phase 2 N=85 Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Ovarian Cancer
Primary: 2-year Progression-free Survival — 40; 40 percentage of participants
Phase 2 N=44 Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants
Phase 2 N=29 Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Sarcoma · Sarcoma Metastatic
Primary: Overall Response Rate — 0; 2 Participants
Phase 2 N=47 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Phase 2 N=36 A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
Peritoneal Cancer · Ovarian Cancer · Neoplasms, Ovarian
Primary: Best Biochemical Response (Cancer Antigen [CA-125]) — 6; 25; 56; 3 percentage of participants
Phase 2 N=36 Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Overall Response Rate — .083 proportion of participants
Phase 2 N=68 S9912 Combination Chemo in Stage III Ovarian Cancer,
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Progression-free Survival — 25 months
Phase 2 N=35 Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
Ovarian Clear Cell Adenocarcinoma · Recurrent Ovarian Carcinoma
Primary: Objective Tumor Response Rate (Complete and Partial Response) — 6.7 percentage of participants
Phase 1 N=13 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Phase 2 N=4 Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Phase 2 N=8 Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Primary Peritoneal Cancer
Primary: The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or…
Phase 2 N=148 A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019
Phase 2 N=24 Gleevec Study for Patients With Ovarian Cancer
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Phase 1 N=28 Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Overview of Treatment-emergent Adverse Events (TEAEs) — 3; 13; 11; 2 Participants
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
N/A N=221 Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 2 N=246 Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Ovarian Neoplasms
Primary: Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment — 386; 478 Days — p=0.655
Phase 2 N=38 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants